Until now, tuberculosis is always a dangerous infectious disease. Because of the enlargement of multidrug-resistant strains (MDR-TB), the need of new drugs becomes more important. Fusing of 2 pharmacophores (phenothiazine and benzopyran), we intend to synthesize some new pyranophenothiazine derivatives, and evaluate their antituberculosis activities. The designed compounds were prepared using conventional synthetic methods with all PA chemical agents (from Merk, TCI, Sigma). The structure of all synthesized compounds had been confirmed by analysis of NMR and MS spectra. Antimycobacterial activity of the synthesized compounds on Mycobacterium bovis BCG (or on the virulent strain Mycobacterium tuberculosis H37Rv for the most promising compounds) had been determined using the Microdilution resazurin assay. 2 compounds 8 and 9 were obtained by Claisen rearrangement of intermediate dimethylpropargyl ether. The sulfoxide and (+)cis-diol sulfoxide derivatives were obtained by oxydation, and the dihydro-derivatives -by reduction of the leader compounds. The anti-tuberculosis activities of 12 synthesized compounds were evaluated. Only the leading compound of linear structure (pyrano[b]phenothiazine) and 2 non-sulfoxide derivatives of angular structure (pyrano[a]phenothiazine) exhibited a mild inhibiting activity on the tested tuberculosis source. 12 new pyrano-phenothiazine compounds have been prepared and bioevaluated. The results showed that 3 compounds exhibited a mild inhibiting activity on the tested tuberculosis source. These structural requirements will be taken into account for the design of further analogues in pyranophenothiazine series.
INTRODUCTION
In 2015, tuberculosis caused estimated 10.4 million new cases worldwide, including about 480 000 new cases of multidrug-resistant TB (MDR-TB) and an additional 100 000 people with rifampicin-resistant TB (RR-TB), and responsed 1.8 million deaths 1 . So it remains one of the most dangerous infectious diseases in the world. The current chemotherapy established more than thirty years ago gives rise, since the 1990s, to multidrug-resistant strains (MDR-TB) particularly among the HIV-infected people where co-infection with M. tuberculosis is responsible of over 50 % of deaths. Consequently, the need of new drugs has never been greater 2, 3 . Intend to create new antituberculosis substances, we would like to hybridize 2 pharmacophores: phenothiazine and 2H-benzopyran (or 2H-chromene) because of their interesting bioactivities.
The phenothiazine (1) had been determined in 1883 by Heinrich August Bernthsen after the synthesis of blue methylene -an antiparasitic compound -in 1876 by Heinrich Caro. After the discovery of chlorpromazine (2) in 1952, more than 5000 phenothiazine derivatives were synthesized and evaluated biological activity, and many substances had been used clinically as anticonvulsant, antipsychotic, antiemetic, antimicrobial, antihistamine, antitumor agent 4 . Several phenothiazine derivatives such as chlorpromazine, thioridazine (3) had showed antituberculosis activity which able to circumvent the MDR resistance [5] [6] [7] [8] . So this tricyclic basic core had been chosen as a part of new antituberculosis structure. The 2H-benzopyran appeared as a "privileged substructure" present in numerous bioactive compounds 9 exemplified by the antifungal benzopyran methylripariochromene A (4) 10 , the antibacterial pyranoflavanone 5-methyllupinifoliol (5) 11 , and the antitumor acridone alkaloid acronycine (6) 12, 13 . In the course of our research, the 3,3-dimethyl-3H-benzofuro[3,2-f][1]-benzopyran (7) had been synthesized and demonstrated promising and specific antituberculosis properties 14, 15 . So the 2H-benzopyran may give an interesting activity for the new structure.
The purpose of this research was to synthesize potential antituberculosis compounds, including a phenothiazine basic core fused with an additional pyran ring, leading to two different series depending of the linear (8) or angular (9) mode of fusion. The double-bond of the fused dimethylpyran ring would be modified, permitting modulation of molecular lipophilicity in the course of structure activity relationship studies.
MATERIALS AND METHODS

Materials
The designed compounds were prepared using conventional synthetic methods with all PA chemical agents (from Merck, TCI, Sigma). IR spectra were recorded on a Nicolet 510 FT-IR spectrophotometer as KBr discs.
1 H and 13 C NMR spectra were recorded on an AC 300 Bruker spectrometer (300 MHz for 1 H and 75 MHz for 13 C) and an Avance 400 Bruker spectrometer. Mass spectra were recorded on a Nermag R 10-10C mass spectrometer (DIC/ NH 3 ) (90eV), or a Hewlett Packard 5890 spectrometer (IE) (70eV), or a ZQ 2000 Waters spectrometer (ESI).
Methods
Chemistry
The synthesis of desired compounds was realized by 2 steps: 1) synthesis of compounds 8 and 9, and 2) synthesis of their derivatives.
In the first step, 2 compounds 8 and 9 were synthesized according to the pathway depicted in scheme 1. A demethylation of 2-methoxyphenothiazine (10) had given 10H-2-hydroxyphenothiazine (11), which was put into the reaction with 3-chloro-3-methylbut-1-yne (12) 16 to form 2-(1,1-dimethyl-propargyloxy)-phenothiazine (13) in overall yield of about 50%. This propargylic ether had been cyclized intramolecularly at high temperature to afford the expected products 8 and 9 at the proportion of 2:1 respectively.
The derivatives of these compounds (8 and 9) were synthesized in the second step according to the pathway depicted in scheme 2.
The hydrogenation of compound 8 or 9 gave reduced product 14 or 15 respectively. In other direction, the oxidation of compound 8 gave the sulfoxyde compound (without hydroxylation) 16 and (+)cis-dihydroxysulfoxyde derivatives 17. The oxidation of 9 gave not only 2 products at different levels of oxidation as happened in linear serie (the sulfoxyde without hydroxylation 18 and the (+)cis-dihydroxysulfoxyde 19) , but also the cis-dihydroxy derivative without sulfoxyde 20.
Each (+)cis-dihydroxy product (17, 19, 20) was treated with excess acetic anhydride in pyridine to give the corresponding diacetate (21, 22, 23).
The structure of all synthesized compounds had been confirmed by analysis of NMR and MS spectra.
Bioactivity
Antimycobacterial activity of the synthesized compounds on Mycobacterium bovis BCG (or on the virulent strain Mycobacterium tuberculosis H37Rv for the most promising compounds) was determined using the Microdilution resazurin assay (MRA) 17 . Resazurin salt powder (Sigma) was prepared at 0.01% (wt/vol) in distilled water, sterilized by filtration through a 0.22 µm membrane and stored at 4°C for a week. Drug stock solutions were prepared in dimethylsulfoxide (DMSO) at concentration of 50 mg/mL and frozen until used. The inocula were prepared from M. tuberculosis H37Rv and M. bovis BCG strains grown in Dubos medium supplemented with 10% ADC enrichment (Difco). 2 µL of two fold serial dilutions of each drug was prepared in 200 µL of Dubos medium directly in 96-well plates at concentrations from 100 to 0.05µg/ mL. Growth controls containing DMSO and isoniazide (from 1 µg/mL to 1 ng/mL) were also included. The plates were covered, sealed and incubated at 37 °C. After 6 days for M. tuberculosis or 8 days for M. bovis, 30 µL of resazurin solution was added to each well and plates were allowed to incubate at 37°C for an additional 24 h. A change from blue to pink indicated reduction of resazurin and therefore bacterial growth. The MIC was defined as the lowest drug concentration that prevented this color change.
RESULTS
Chemistry
12 pyranophenothiazines had been synthesized. The information of their spectra of 1 H -NMR, 13 C-NMR, MS, and IR was given below.
10H-2-Hydroxyphenothiazine (11) : amorphous white product: UV (MeOH) λ max : 
Bioactivity:
The antimycobacterial activity was screened on Mycobacterium bovis BCG using the new Microdilution resazurin assay 17 (table 1) . The most promising compounds (8, 20, 23) were evaluated on the virulent strain Mycobacterium tuberculosis H37Rv by the same method 17 (table 2) . (17, 19, 20) with excess acetic anhydride gave the corresponding diacetates (21, 22, 23) At this part, 12 new pyranophenothiazine derivatives had been prepared. Their structures had been confirmed by spectra of 1 H -NMR, 13 C-NMR, MS.
In fact, the molecular mass of each compound corresponded to its molecular structure.
All 1 H -NMR spectra contained the numbers of proton corresponding to their structures, with 2 peaks of 3H at about 1.3 ppm, corresponding to 2 methyl groups on pyran ring; 6 peaks 1H in the aromatic zone (from 8 to 5 ppm) attributed to the 6 proton of the phenothiazine ring; and 1 large single peak rather far from other peaks, about 10-9 ppm, corresponding to proton of NH on phenothiazine ring.
The spectra of 3 diol compounds (17, 19, 20) showing 2 peaks, which had disappeared with D 2 O, confirmed the presence of 2 hydroxyl groups. The presence of diacetate groups on the spectra of 3 derivatives 21, 22, 23 were confirmed by 2 single peaks of 3H at about 2 ppm and the disappearance of 2 peaks of the 2 hydroxyl groups in comparison with the spectra of the corresponding diol.
All structures were confirmed by respective 13 C -NMR spectra. (table 2) . Their activities were more potent on this strain with MIC 95 of 6.2 μg/mL and equivalent of those of the initial hits 3,3-dimethyl-3H-benzofuro [3,2-f] [1]-benzopyran 7 and its reduced analogue (MIC 95 of 10 µg/ml) previously prepared by our collaborators 14 .
These results showed that linearly fused compounds could be more potent than the angularly fused one. Compound 8 exhibited an interesting activity whereas its angular counterpart 9 was inactive. Any ways, the (+)-cis-diol and (+)-cis-diacetate derivatives of angular series presented an activity comparable with compound 8 of linear series promising an favorable activity of (+)-cis-diol and (+)-cisdiacetate derivatives in linear series.
In both series, all sulfoxide derivatives were devoid of activity. This could be explain by the drastic loss of lipophilicity (CLogP of sulfoxyde 16: 2.7 versus ClogP of 8: 5.1), which was in good agreement with previous observations for major antitubercular drugs, especially due to the lack of penetration of compounds on the mycobacterial cell wall.
CONCLUSION
In conclusion, 12 new pyranophenothiazine derivatives had been prepared. Their structures were confirmed by analysis of suitable spectral data ( 1 H-NMR, 13 C-NMR and MS). Their antibacterial activity was evaluated on Mycobacterium bovis BCG. Three most active compounds (8, 20, 23) were tested on the virulent Mycobacterium tuberculosis H37Rv. As a general rule, active derivatives were more potent on Mycobacterium tuberculosis than on M. bovis indicating a good selectivity. These structural requirements will be taken into account for the design of further analogues in pyranophenothiazine series.
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